Invention:
This invention is for a novel small molecule therapy for the treatment of Pancreatic ductal adenocarcinoma (PDAC). This new set of compounds contain inhibitors that have shown successfully slowed tumor progression by reducing expression of two major tumor-causing mutated oncoproteins in mouse models.
Background:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of cancer and typical therapeutic options fail to hit the mark as drug toxicity affects the efficacy of common treatment options. This new therapeutic provides a new way to increase efficacy of existing options, allowing for the extension of PDAC patient lifespan.
Applications:
- Pancreatic ductal adenocarcinoma (PDAC) therapeutic
- Pancreatic cancer therapeutics
- Oncology research
Advantages:
- Overall decrease in cell life of two major oncoproteins
- Demonstration of in vivo anti-tumor activity in live hosts
- Proven tumor grown inhibition after treatment
- Lack of toxicity and weight changes within treated individuals
